SEARCH

SEARCH BY CITATION

References

  • 1
    Warner JO, Marguet C, Rao R, Roche WR, Pohunek P. Inflammatory mechanisms in childhood asthma. Clin Exp Allergy 1998;28(Suppl. 5):7175.
  • 2
    Djukanovic R, SterkPJ, FahyJV, HargreaveFE (editors). Standardised methodology of sputum induction and processing. Eur Resp J 2002;20(Suppl. 37):S1S55.
  • 3
    Piacentini GL, Bodini A, Costella S, Vicentini L, Mazzi P, Sperandio S et al. Exhaled nitric oxide and sputum eosinophil markers of inflammation in asthmatic children. Eur Resp J 1999;13: 13861390.
  • 4
    Wilson NM, Bridge P, Spanevello A, Silverman M. Induced sputum in children: feasibility, repeatability, and relation of findings to asthma severity. Thorax 2000;55: 768774.
  • 5
    Cai Y, Carty K, Henry RL, Gibson PG. Persistence of sputum eosinophilia in children with controlled asthma when compared with healthy children. Eur Resp J 1998;11: 848853.
  • 6
    Gibson PG, Norzila MZ, Fakes K, Simpson J, Henry RL. Pattern of airway inflammation and its determinants in children with acute severe asthma. Pediatr Pulmonol 1999;28: 261270.
  • 7
    Grootendorst DC, van den Bos J-W, Romeijn JJ, Veselic-Charvat M, Duiverman EJ, Vrijlandt EJLE et al. Induced sputum in adolescents with severe stable asthma. Safety and the relationship of cell counts and eosinophilic cationic protein to clinical severity. Eur Resp J 1999;13: 647653.
  • 8
    WarnerJO, NaspitzCK (eds). Third International Pediatric Consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group. Pediatr Pulmol 1998;25: 117.
  • 9
    National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma – update on selected topics, 2002. Bethesda (MD): National Institutes of Health; 2002. J Allergy Clin Immnunol 2002;110: S141S218.
  • 10
    Zeiger RS, Dawson C, Weiss S. Relationship between duration of asthma and asthma severity among children in the Childhood Asthma Management program. J Allergy Clin Immunol 1999;103: 376387.
  • 11
    Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331: 700705.
  • 12
    Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR et al. Effect of inhaled corticosteroids on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992;145: 669674.
  • 13
    Jatakanon A, Kharitonov S, Lim S, Barnes PJ. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999;54: 108114.
  • 14
    The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000;343: 10541063.
  • 15
    ERS Task Force on standardization and interpretation strategies. Clinical exercise testing with reference to lung disease: indications, standardization and interpretation strategies. Eur Resp J 1997;10: 26622689.
  • 16
    Koillinen H, Wanne O, Niemi V, Laakonen E. Spirometric and peak expiratory flow reference values of healthy Finnish children. Finnish Med J 1998;53: 395402.
  • 17
    Pelkonen AS, Hakulinen AL, Turpeinen M. Bronchial lability and responsiveness in schoolchildren born very preterm. Am J Respir Crit Care Med 1997;156: 11781184.
  • 18
    DreborgS (editor). Skin tests used in type I allergy testing. Position paper. Allergy 1989;44(Suppl.10):159.
  • 19
    American Thoracic Society (ATS). Standardization of spirometry – 1994 update. Am Rev Respir Dis 1995;152: 11071136.
  • 20
    Sovijärvi ARA, Malmberg P, Reinikainen K, Rytilä P, Poppius H. A rapid dosimetric method with controlled tidal breathing for histamine challenge. Repeatability and distribution of bronchial reactivity in a clinical material. Chest 1993;104: 164170.
  • 21
    Malmberg LP, Nikander K, Pelkonen A, Syvänen P, Koljonen T, Haahtela T et al. Acceptability, reproducibility, and sensitivity of forced expiratory volumes and peak expiratory flow during bronchial challenge testing in child asthmatics. Chest 2001;120: 18431849.
  • 22
    Sorva R, Metso T, Turpeinen M, Juntunen-Backman K, Björkstén F, Haahtela T. Eosinophil cationic protein in induced sputum as a marker of inflammation in asthmatic children. Pediatr Allergy Immunol 1997;8: 4550.
  • 23
    Fahy JV, Liu J, Wong H, Boushey HA. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993;147: 11261131.
  • 24
    In'tVeen JCCM, de Gouw HWFM, Smits HH, Sont JK, Hiemstra PS, Sterk PJ et al. Repeatability of cellular and soluble markers of inflammation in induced sputum of patients with asthma. Eur Resp J 1996;9: 24412447.
  • 25
    Kips JC, Indman MD, Jayaram L, Bel EH, Parameswaran K, Pizzichini MMM et al. The use of induced sputum in clinical trials. Eur Resp J 2002;20: 47s50s.
  • 26
    Payne DN, Rogers AV, Ädelroth E, Bandi V, Guntupalli KK, Bush A et al. Early thickening of the reticular basement membrane in children with difficult asthma. Am J Respir Crit Care Med 2003;167: 7882.
  • 27
    Malmberg LP, Pelkonen AS, Haahtela T, Turpeinen M. Exhaled nitric oxide rather than lung function distinguishes preschool children with probable asthma. Thorax 2003;58: 494499.
  • 28
    Gibson PG, Simpson JL, Hankin R, Powell H, Henry RL. Relationship between induced sputum eosinophils and clinical pattern of childhood asthma. Thorax 2003;58: 116121.
  • 29
    Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999;353: 22132214.